<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04189588</url>
  </required_header>
  <id_info>
    <org_study_id>TER-QZTR-001</org_study_id>
    <nct_id>NCT04189588</nct_id>
  </id_info>
  <brief_title>Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine</brief_title>
  <acronym>versus</acronym>
  <official_title>A Phase 2 Exploratory Study of Intravenous QUZYTTIR™ (Cetirizine Hydrochloride Injection) Versus Intravenous Diphenhydramine in the Prevention of Hypersensitivity Infusion Reactions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TerSera Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TerSera Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to compare the incidence of infusion reactions to treatment with
      Rituxan® (rituximab) after premedication with intravenous (IV) QUZYTTIR™ cetirizine
      hydrochloride (HCl) or IV diphenhydramine during first-cycle infusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized, double-blind exploratory study of IV cetirizine HCl 10 mg/mL
      versus IV diphenhydramine 50 mg/mL in approximately 34 patients who require premedication for
      hypersensitivity infusion reactions associated with Rituxan (rituximab).

      The objectives and purpose of the study will be described to patients presenting at the
      participating infusion centers. The patients will be randomized to receive either IV
      cetirizine HCl or IV diphenhydramine.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 24, 2020</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Randomized Double Blind Study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Hypersensitivity Reactions to Treatment</measure>
    <time_frame>1 Month</time_frame>
    <description>Compare the incidence of infusion reactions (ﬂushing, itching, alterations in heart rate and blood pressure, dyspnea, chest discomfort, acute back or abdominal pain, fever, shaking chills, nausea, vomiting, diarrhea, skin rashes, throat tightening, hypoxia, seizures, dizziness, or syncope) to treatment with Rituxan® (rituximab) after premedication with intravenous (IV) QUZYTTIR™ cetirizine hydrochloride (HCl) or IV diphenhydramine during first-cycle infusion.(rituximab) with premedication of IV cetirizine HCl or IV diphenhydramine as a premedication.
The infusion reactions will be evaluated following the Common Terminology Criteria for Adverse Events (CTCAE version 5.0) deﬁnitions of graded infusion reactions.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Oncology Patients Receiving Chemotherapy</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cetirizine HCl 10 mg/mL: a single 1 mL injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diphenhydramine 50 mg/mL: a single 1 mL injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetirizine HCl 10 mg/mL</intervention_name>
    <description>Comparison of two injectable products: cetirizine HCl 10 mg/mL and diphenhydramine 50 mg/mL, both administered during a 1 to 2-minute period by IV push using a 1 mL syringe</description>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine 50 mg/mL</intervention_name>
    <description>Comparison of two injectable products: cetirizine HCl 10 mg/mL and diphenhydramine 50 mg/mL, both administered during a 1 to 2-minute period by IV push using a 1 mL syringe</description>
    <arm_group_label>Cohort A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituxan® (rituximab)</intervention_name>
    <description>Compare the incidence of infusion reactions to treatment with Rituxan® (rituximab) after premedication with intravenous (IV) QUZYTTIR™ cetirizine hydrochloride (HCl) or IV diphenhydramine during first-cycle infusion.</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients who will receive treatment premedication with an antihistamine
             for hypersensitivity infusion reactions associated with Rituxan (rituximab)

          -  18 years of age or older

        Exclusion Criteria:

          -  Receipt of an investigational drug or device within the past 30 days.

          -  Patients with likelihood of developing or history of tumor lysis syndrome.

          -  Patients in whom an antihistamine may be contraindicated (e.g., narrow angle glaucoma,
             symptomatic prostatic hypertrophy).

          -  Patients who, in the opinion of the investigator, may not tolerate an IV injection of
             diphenhydramine 50 mg or cetirizine HCl 10 mg.

          -  Receipt of any antihistamine (H1 antagonist) within the past 2 hours regardless of the
             route of administration, e.g., diphenhydramine, cetirizine, loratadine, fexofenadine,
             levocetirizine, desloratadine. chlorpheniramine, clemastine and doxylamine

          -  Receipt of an H2 antagonist within the past 4 hours, e.g., ranitidine, cimetidine,
             famotidine, nizatidine.

          -  Receipt of doxepin within the past 24 hours; doxepin is an antidepressant, but it also
             has antihistamine properties.

          -  Receipt of epinephrine (EpiPen® or any other brand) within the past 30 days.

          -  Has known allergy to hydroxyzine, cetirizine, or levocetirizine, or diphenhydramine.

          -  Pregnant or breastfeeding.

          -  Any condition that in the view of the investigator makes the patient unsuitable for
             enrollment in this study.

          -  Major medical or psychiatric illness, other than diagnosed cancer at the time of
             presentation or in the past that in the investigators judgement they should not be
             enrolled in this clinical trial.

          -  Inability to provide informed consent.

          -  Patients on concomitant P-glycoprotein inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nancy Joseph-Ridge, M.D.</last_name>
    <phone>847-604-4058</phone>
    <email>njridge@tersera.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eisenhower Medical Center</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Constantin Dasanu, MD/PhD</last_name>
      <phone>760-346-7655</phone>
    </contact>
    <investigator>
      <last_name>Constantin Dasanu, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph Heritage Healthcare</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Young, RN, CCRC</last_name>
      <phone>707-521-3814</phone>
    </contact>
    <contact_backup>
      <last_name>Research Department</last_name>
      <phone>707-521-3830</phone>
    </contact_backup>
    <investigator>
      <last_name>Jarrod P Holmes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor, Scott, &amp; White Medical Center</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78665</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Herrington, Pharm D</last_name>
      <phone>254-724-4829</phone>
    </contact>
    <investigator>
      <last_name>John D Herrington, Pharm D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor, Scott, &amp; White Medical Center</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>96508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Herrington, Pharm D</last_name>
      <phone>254-724-4829</phone>
    </contact>
    <investigator>
      <last_name>John Herrington, Pharm D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor, Scott, &amp; White Medical Center</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John D Herrington, Pharm D</last_name>
      <phone>254-724-4829</phone>
    </contact>
    <investigator>
      <last_name>John D Herrington, Pharm D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 3, 2019</study_first_submitted>
  <study_first_submitted_qc>December 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2019</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Cetirizine</mesh_term>
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

